Substance / Medication

Estramustine phosphate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.

Lubiniecki Gregory M, Berlin Jesse A, Weinstein Rachel B et al. · Cancer · 2004

PMID: 15536625Meta-Analysis

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Hirano Daisaku, Nagane Yusuke, Satoh Katsuhiko et al. · Int Urol Nephrol · 2010

PMID: 19449118RCT

Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.

Inoue Takahiro, Ogura Keiji, Kawakita Mutushi et al. · Clin Genitourin Cancer · 2016

PMID: 26433627Trial

Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.

Petrioli Roberto, Roviello Giandomenico, Fiaschi Anna I et al. · Clin Genitourin Cancer · 2015

PMID: 25920994Trial

Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.

Narita Shintaro, Tsuchiya Norihiko, Yuasa Takeshi et al. · Int J Clin Oncol · 2012

PMID: 21706123Trial

Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study.

Koie T, Ohyama C, Yamamoto H et al. · Prostate Cancer Prostatic Dis · 2012

PMID: 22890389Trial

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.

Noguchi Masanori, Kakuma Tatsuyuki, Uemura Hirotsugu et al. · Cancer Immunol Immunother · 2010

PMID: 20146063TrialFull text (PMC)

Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.

Spitaleri G, Matei D V, Curigliano G et al. · Ann Oncol · 2009

PMID: 19139180Trial

Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.

Pectasides Dimitrios, Pectasides Eirini, Papaxoinis George et al. · Anticancer Res · 2009

PMID: 19331234Trial

A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.

Baz Walid, Nakhl Fadi, El-Soueidi Raymond et al. · Anticancer Drugs · 2009

PMID: 19318913Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Estramustine phosphate (substance)
SNOMED CT: 326745006
UMLS CUI: C0356799

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.